FEB 22, 2018 06:00 AM PST

Developing Personalized Cancer Neoantigen Vaccines

C.E. CREDITS: P.A.C.E. CE | Florida CE
  • Chief Scientific Officer, Vaccibody AS
      Agnete B. Fredriksen is Co-Founder and joined Vaccibody in 2007. She holds a MSc, PhD from Institute of Immunology, Rikshospitalet Medical Center in Oslo where she designed and developed the first Vaccibody vaccine molecules. She received the King's Gold Medal for her PhD thesis describing Vaccibodies. Her focus is on cancer vaccines from idea to clinical development. Previous employment includes Affitech AS and Medinnova AS. Agnete is author on numerous scientific papers in the field of immunology, immunotherapy and vaccines. Inventor on several patents in the field of immunotherapy. She is board member for the BIA programme of NRC stimulating research in the Norwegian industry.


    Vaccibody has developed a unique platform technology able to substantially potentiate vaccines by an inherent mechanism that attract, activate and deliver antigens to antigen presenting cells. Currently, Vaccibody is heavily focusing on using the platform technology to generate unique individualized cancer neoantigen vaccines. Recent clinical data indicate an important role of T cell immunity to cancer neoantigens in patients that benefit from immunotherapies. A cancer neoantigen vaccine should be customized for each individual patients cancer-specific somatic mutations and hence warrant manufacturing of one vaccine per patient. By using the DNA vaccine format encoding for the Vaccibody protein, a rapid, cost-effective and robust manufacturing process has been generated which lends itself perfectly to develop commercially viable patient-specific vaccines on demand. Supportive preclinical data with neoantigen based DNA vaccines as well as clinical data with a similar Vaccibody DNA vaccine using viral antigens support a favourable safety, tolerability and efficacy profile. A clinical study using targeted Vaccibody neoepitope DNA vaccines in multiple advanced cancer indications is planned to start Q1 2018.

    Show Resources
    Loading Comments...